If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

Share Price is delayed by 15 minutes
Get Live Data
170.50    -1.50 (-0.87%)
Bid:
168.50
Ask:
171.50
Spread: 3.00 (1.78%)
Market Cap: £1.47b
HCM Live PriceLast checked at - London Stock Exchange

Intraday Hutchmed Share Chart

Director/PDMR Shareholding

23 Mar 2007 07:00

Hutchison China Meditech Limited23 March 2007 Hutchison China MediTech Limited (AIM: HCM) Director's Shareholding London: Friday, 23 March 2007: Hutchison China MediTech Limited ("Chi-Med") wasinformed on 22 March 2007 that Mr. Christian Hogg, Executive Director and ChiefExecutive Officer of Chi-Med, purchased 100,000 ordinary shares of US$1 each inChi-Med (the "Shares") at a price of 172p each on 22 March 2007. Following this purchase, Mr. Hogg is beneficially interested in 100,000 Shares,representing approximately 0.2% of the current issued share capital of Chi-Med. Ends Enquiries Chi-Med Telephone: +852 2121 8200 Christian Hogg, CEO Citigate Dewe Rogerson Telephone: +44 (0) 20 7638 9571 Anthony Carlisle Mobile: +44 (0) 7973 611 888Yvonne Alexander Mobile: +44 (0) 7866 610 682 About Chi-Med Chi-Med is the holding company of a pharmaceutical and healthcare group basedprimarily in China and was admitted to trading on the Alternative InvestmentMarket of the London Stock Exchange in May 2006. Chi-Med is focused onresearching, developing, manufacturing, and selling pharmaceuticals, healthsupplements and other consumer health and personal care products derived fromTraditional Chinese Medicine and botanical ingredients. Chi-Med is majority owned by Hutchison Whampoa Limited, an internationalcorporation listed on the Main Board of The Stock Exchange of Hong Kong Limited. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
4th Mar 202112:00 pmRNSFinal Results, Business Update and Name Change
3rd Feb 20217:00 amRNSNotice of Results
14th Jan 202110:00 amRNSSavolitinib Data to be Presented at Virtual WCLC
11th Jan 20217:00 amRNSChi-Med & Inmagene Announce Strategic Partnership
31st Dec 20207:00 amRNSBlocklisting Six Monthly Return
31st Dec 20207:00 amRNSTotal Voting Rights
30th Dec 202012:00 pmRNSNMPA approval of Surufatinib in China for ep-NET
29th Dec 20207:45 amRNSUS NDA Rolling Submission of Surufatinib Initiated
22nd Dec 20207:00 amRNSChi-Med to Present at JPM
15th Dec 20209:45 amRNSGrant of Share Options under Share Option Scheme
30th Nov 20207:00 amRNSTotal Voting Rights
27th Nov 20207:00 amRNSNotification of Dilution of Voting Rights
17th Nov 20207:00 amRNSUS$100m Equity Investment by CPP Investments
5th Nov 20209:00 amRNSChi-Med to Present HMPL-689 Clinical Data at ASH
30th Oct 202012:00 pmRNSChi-Med to Attend Upcoming Conferences
30th Oct 20207:00 amRNSTotal Voting Rights
30th Sep 20207:00 amRNSTotal Voting Rights
21st Sep 20207:00 amRNSSurufatinib Data at ESMO and in Lancet Oncology
17th Sep 202011:45 amRNSSecond Chinese NDA Acceptance for Surufatinib
4th Sep 20207:00 amRNSChi-Med Initiates Global Phase III Trial
3rd Sep 20207:00 amRNSChi-Med Initiates a Phase II Trial
28th Aug 202011:30 amRNSTotal Voting Rights
24th Aug 20207:00 amRNSClinical Data to be Presented at ESMO 2020
12th Aug 202010:30 amRNSGrant of Share Options under Share Option Scheme
10th Aug 20207:00 amRNSSurufatinib Marketing Authorization Application
30th Jul 202012:00 pmRNSInterim Results and Clinical Update
30th Jul 20207:00 amRNSBlock Admission Application
28th Jul 20207:00 amRNSChi-Med & Lilly Collaborate on Elunate in China
28th Jul 20207:00 amRNSSavolitinib NDA Granted Priority Review in China
24th Jul 20207:00 amRNSChi-Med Initiates HMPL-306 Phase I Trial in China
8th Jul 20208:00 amRNSHolding(s) in Company
7th Jul 20208:00 amRNSHolding(s) in Company
7th Jul 20207:00 amRNSNotification of Dilution of Voting Rights
29th Jun 20207:00 amRNSBlocklisting Six Monthly Return
26th Jun 20207:00 amRNSNotice of Results
25th Jun 20207:15 amRNS$100 Million Equity Investment by General Atlantic
18th Jun 20208:15 amRNSFruquintinib Granted US FDA Fast Track Designation
9th Jun 20207:00 amRNSUS$95m Guangzhou Land Compensation Agreement
4th Jun 20207:00 amRNSContinuation of Phase III FRUTIGA Study
2nd Jun 20204:40 pmRNSSecond Price Monitoring Extn
2nd Jun 20204:37 pmRNSPrice Monitoring Extension
1st Jun 20207:00 amRNSChi-Med Plans to Submit US NDA for Surufatinib
29th May 20201:00 pmRNSChi-Med to Discuss Data Presented at ASCO20
29th May 20207:00 amRNSNDA Acceptance in China for Savolitinib
26th May 20207:00 amRNSChi-Med and BeiGene Enter Clinical Collaboration
14th May 20207:00 amRNSClinical Data to be Presented at ASCO20
11th May 20204:41 pmRNSSecond Price Monitoring Extn
11th May 20204:36 pmRNSPrice Monitoring Extension
11th May 20207:00 amRNSChi-Med to Attend Upcoming Investor Conferences
29th Apr 202011:45 amRNSGrant of Share Options under Share Option Scheme

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.